Microbial Diagnostics and Surveillance (MIDAS)

Working to provide tools for the rapid identification of bacterial and viral genomes for diagnostic and public health laboratories.

Contact us »

This consortium will develop technological solutions that use the entire genomes of viruses and bacteria to support healthcare decision making. We aim to make this as straightforward as possible to perform, so that the technology can be introduced into diagnostic and public health laboratories across the UK, where it will provide information in real time on bacterial and viral spread and outbreaks in hospitals and the community.

This website provides a central repository for the metadata concerning the bacterial and virus genomes sequenced and deposited by all members of the consortium.

The partnership utilises whole genome sequencing of a number of important hospital/community acquired bacterial species to enable effective surveillance. This will be used to track disease trends, identify new infectious disease threats, detect serious outbreaks, monitor control measures and assess antibiotic resistance to enable the most effective treatment to be offered.

Infection Response through Virus Genomics (ICONIC) uses next generation sequencing technology aiming to support clinical decisions for patient treatment and hospital infection control responses, and inform the surveillance of viral outbreaks in the community. ICONIC is designed in ways that allow this technology to be incorporated fully within the UK local diagnostic labs, adding sustainable patient benefit with minimal cost. In so doing, we embed into the NHS the ability to respond rapidly to new and emerging viral infections in the future.

The Modernising Medical Microbiology (MMM) consortium are developing a pathogen sequencing solution for identifying, typing and tracking microbes. The project aims to show that accurate diagnosis can happen in a local lab fast and cheaply enough to improve patient outcomes e.g. by getting more appropriate drugs faster. The results will also allow us to minimise the over-use of precious antibiotics. In turn this will reduce the incidence of antibiotic resistance and multi-resistance of bugs, reduce the risk of infections and provide cost savings in the NHS.